Stage IV Rectal Cancer with Liver Metastases: Is There a Benefit to Resection of the Primary Tumor?

被引:23
|
作者
Cellini, Christina [1 ]
Hunt, Steven R. [1 ]
Fleshman, James W. [1 ]
Birnbaum, Elisa H. [1 ]
Bierhals, Andrew J. [2 ]
Mutch, Matthew G. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, Sect Colon & Rectal Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
关键词
COLORECTAL-CANCER; NONOPERATIVE MANAGEMENT; PALLIATIVE RESECTION; SURGICAL RESECTION; CHEMOTHERAPY; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; COMBINATION;
D O I
10.1007/s00268-010-0483-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases. For patients with extensive liver metastases, FOLFOX and FOLFIRI have improved resection rates and survival. We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all. Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008. Patients received neoadjuvant chemoradiation and adjuvant FOLFOX or FOLFIRI therapy. The outcomes for patients who underwent synchronous resection, staged resection, resection of rectal tumor only, and no resection with chemotherapy only were compared. Statistical analysis was determined by ANOVA. Survival was determined using the Kaplan-Meier method. Seventy-four patients were identified: 30 synchronous resections, 13 staged resections, 22 primary resection only, and 9 no resection. Median follow-up was 23 months (range = 4-58 months). Sixty-five percent of patients underwent liver resection with 26% rendered eligible for resection after adjuvant therapy. Those who underwent primary resection only had shorter median survival than those who underwent either staged or synchronous liver resection (31 vs. 47 vs. 46 months, respectively; P = 0.17). Survival was no different for synchronous versus staged resection (P = 0.6). Volume of liver disease predicted resectability (P = 0.001). Without liver resection, 2-year survival was approximately 60%. Palliative surgery was required in six of nine patients who did not undergo resection of their primary tumor. Current chemotherapeutic regimens lead to improved survival in patients with unresectable liver metastases. Upfront chemotherapy in the asymptomatic patient compared with resection of the primary tumor does not appear to significantly affect survival. However, given that 60% of patients were alive after 2 years, resection of the primary lesion for palliative reasons and local control must be considered.
引用
收藏
页码:1102 / 1108
页数:7
相关论文
共 50 条
  • [21] Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease
    Garrett M. Nash
    Leonard B. Saltz
    Nancy E. Kemeny
    Bruce Minsky
    Sunil Sharma
    Gary K. Schwartz
    David H. Ilson
    Eileen O’Reilly
    David P. Kelsen
    Daniel R. Nathanson
    Martin Weiser
    Jose G. Guillem
    W. Douglas Wong
    Alfred M. Cohen
    Philip B. Paty
    Annals of Surgical Oncology, 2002, 9 : 954 - 960
  • [22] Propensity-score matched outcomes of resection of stage IV primary colon cancer with and without simultaneous resection of liver metastases
    Emile, Sameh Hany
    Horesh, Nir
    Garoufalia, Zoe
    Gefen, Rachel
    Zhou, Peige
    Wexner, Steven D.
    UPDATES IN SURGERY, 2024, 76 (03) : 845 - 853
  • [23] Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis
    Maroney, Sean
    de Paz, Carlos Chavez
    Reeves, Mark E.
    Garberoglio, Carlos
    Raskin, Elizabeth
    Senthil, Maheswari
    Namm, Jukes P.
    Solomon, Naveenraj
    JOURNAL OF GASTROINTESTINAL SURGERY, 2018, 22 (03) : 460 - 466
  • [24] Benefit of Surgical Resection of the Primary Tumor in Patients Undergoing Chemotherapy for Stage IV Colorectal Cancer with Unresected Metastasis
    Sean Maroney
    Carlos Chavez de Paz
    Mark E. Reeves
    Carlos Garberoglio
    Elizabeth Raskin
    Maheswari Senthil
    Jukes P. Namm
    Naveenraj Solomon
    Journal of Gastrointestinal Surgery, 2018, 22 : 460 - 466
  • [25] Who can get the survival benefit of primary tumor resection for de novo stage IV breast cancer?
    Shien, Tadahiko
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (06) : 2184 - 2185
  • [26] Liver-First Approach to Stage IV Rectal Cancer with Synchronous Isolated Liver Metastases
    Kurbatov, V.
    Resio, B.
    Heller, D. R.
    Salem, R. S.
    Cha, C.
    Lu, J.
    Blasberg, J.
    Zhang, Y.
    Khan, S.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S128 - S128
  • [27] Impact of primary tumor stage on survival following resection of metachronous liver and/or lung metastases in colorectal cancer
    Wong, Hui-Li
    Boolell, Vishal
    Kosmider, Suzanne
    Field, Kathryn Maree
    Wong, Rachel
    Shapiro, Jeremy David
    Cooray, Prasad
    Hayes, Ian
    Faragher, Ian
    Steel, Malcolm
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection
    Gangi, Alexandra
    Manguso, Nicholas
    Gong, Jun
    Crystal, Jessica S.
    Paski, Shirley C.
    Hendifar, Andrew E.
    Tuli, Richard
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (11) : 4525 - 4532
  • [29] Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection
    Alexandra Gangi
    Nicholas Manguso
    Jun Gong
    Jessica S. Crystal
    Shirley C. Paski
    Andrew E. Hendifar
    Richard Tuli
    Annals of Surgical Oncology, 2020, 27 : 4525 - 4532
  • [30] Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer
    Musri, Fatma Yalcin
    Mutlu, Hasan
    Karaagac, Mustafa
    Eryilmaz, Melek Karakurt
    Gunduz, Seyda
    Artac, Mehmet
    JOURNAL OF GASTRIC CANCER, 2016, 16 (02) : 78 - 84